poisar

Stocks · News reference

Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

Aug 11, 2026, 8:55 PMBenzinga Newsdesk

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AARD
Source
benzinga
Observed
Aug 11, 2026, 8:55 PM
Checked
Aug 11, 2026, 8:55 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 12:50 PMGrabar Law Office

    Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your Behalf

    Grabar Law Office announced investigations into shareholder claims against four companies: Aardvark Therapeutics for allegedly misleading statements about drug safety leading to 56% stock decline; Flotek Industries for misrepresentations regarding a terminated Puerto Rico power project; GoDaddy for failing to disclose impact of promotional pricing on bookings; and Hub Group for material financial statement misstatements. Long-term shareholders may pursue corporate reforms and compensation.

    Read original at globenewswire-inc
    AARDFTKGDDYHUBG